Fate Therapeutics Company Profile (NASDAQ:FATE)

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Fate Therapeutics, Inc. (NASDAQ:FATE) announced its quarterly earnings results on Monday, August, 14th. The company reported ($0.23) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.24) by $0.01. The firm had revenue of $1.03 million for the quarter, compared to analysts' expectations of $1.02 million. Fate Therapeutics had a negative return on equity of 67.35% and a negative net margin of 887.68%. View Fate Therapeutics' Earnings History.

4 brokerages have issued twelve-month target prices for Fate Therapeutics' stock. Their forecasts range from $6.00 to $8.00. On average, they expect Fate Therapeutics' stock price to reach $7.00 in the next twelve months. View Analyst Ratings for Fate Therapeutics.

Here are some recent quotes from research analysts about Fate Therapeutics stock:

• 1. HC Wainwright analysts commented, "With FDA clearing the Investigational New Drug application (IND) for FATE-NK100, we believe Fate made considerable progress to advance its adaptive natural killer (NK) cell program. As the first program of its type, we believe there could have been considerable delays, but we are encouraged by the FDA's decision and would expect similar regulatory approvals in Canada and the UK in the coming quarter. Fate intends to begin its Phase 1 trial in patients with advanced acute myeloid leukemia (AML) with an accelerated doseescalation scheme, agreed to by the FDA, which would employ a single patient at each of four dose levels, provided no dose-limiting toxicities are observed. Once the target therapeutic dose has been safely reached, Fate intends to dose six additional patients. We expect Fate's collaborator at the University of Minnesota (UMN) will be able to enroll this trial briskly and we would expect to see data presented at a medical forum in 2H17. We believe investigators will be looking for a 30% complete response rate, in other words, at least as good as UMN was seeing with its own research. In addition to response rate, Fate will look at disease free survival, minimal residual disease, and persistence. We expect Fate to explore NK100 in solid tumors, submitting a protocol evaluating NK100 in gynecologic malignancies, targeting a mid-2017 start. Separately, we expect NK100 to be evaluated in a combination study with its own IND; we expect a submission in the next couple months. Although we do not include NK100 in our valuation, we believe that positive clinical data could drive significant upside." (3/20/2017)
• 2. BMO Capital Markets analysts commented, "We are raising our price target to $7 from $4, following 4Q16 earnings that underlined growing interesting in Fate's earlier stage assets, NK100 and iPSC. Our DCF valuation increases as we assign value for these therapies to continue revenue growth beyond ProTmune. We expect ProTmune Phase I interim data in mid-2017 and NK100 to enroll its first AML patient in 2Q17. Fate's hnCD16-iNK could start human trials by early 2018. While we see tremendous potential in the NK100 and iPSC platforms, we wait for clinical validation before including them in our model." (3/17/2017)
• 3. According to Zacks Investment Research, "Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. " (3/7/2017)

Some companies that are related to Fate Therapeutics include Circassia Pharmaceuticals PLC (CIR), Bellicum Pharmaceuticals (BLCM), Catalyst Pharmaceuticals (CPRX), DURECT Corporation (DRRX), Ardelyx (ARDX), uniQure N.V. (QURE), ObsEva SA (OBSV), TOCAGEN INC (TOCA), Immune Design Corp. (IMDZ), UROGEN PHARMA (URGN), Chimerix (CMRX), Pieris Pharmaceuticals (PIRS), Kindred Biosciences (KIN), Stemline Therapeutics (STML), Madrigal Pharmaceuticals (MDGL), Athersys (ATHX), Zymeworks (ZYME) and Cascadian Therapeutics (CASC).

Fate Therapeutics' management team includes the folowing people:

• William H. Rastetter Ph.D., Independent Chairman of the Board
• J. Scott Wolchko, President, Chief Executive Officer, Principal Executive Officer, Director
• John D. Mendlein Ph.D., Vice Chairman of the Board
• Daniel D. Shoemaker Ph.D., Chief Scientific Officer
• John Ferraro, Vice President - Clinical Operations
• Wendy Levin, Vice President - Clinical Development
• Walter Grubb, Vice President - Business Development
• Cindy Tahl J.D., General Counsel
• Stewart Abbot Ph.D., Chief Development Officer
• Chris M. Storgard M.D., Chief Medical Officer

Fate Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (14.68%), FMR LLC (10.50%), EcoR1 Capital LLC (6.13%), Redmile Group LLC (3.43%), Vanguard Group Inc. (3.05%) and Kingdon Capital Management L.L.C. (2.78%). Company insiders that own Fate Therapeutics stock include Chris Storgard and William H Rastetter. View Institutional Ownership Trends for Fate Therapeutics.

Fate Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C., FMR LLC, Goldman Sachs Group Inc., Wells Fargo & Company MN and Neuberger Berman Group LLC. View Insider Buying and Selling for Fate Therapeutics.

Fate Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Northern Trust Corp, TIAA CREF Investment Management LLC, Vanguard Group Inc., Algert Global LLC, Bank of New York Mellon Corp, OxFORD Asset Management LLP and Teachers Advisors LLC. Company insiders that have bought Fate Therapeutics stock in the last two years include Chris Storgard and William H Rastetter. View Insider Buying and Selling for Fate Therapeutics.

Shares of Fate Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Fate Therapeutics stock can currently be purchased for approximately $3.18.